Blueprint beats Deciphera to the punch
In the battle between two Kit/PDGFRα kinase inhibitors first blood goes to Blueprint’s avapritinib.
ASN 2019 preview – fears grow that roxadustat could come up short
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
Triple meeting – clinical data, and competition, loom for Mirati
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
Novo goes early to leapfrog haemophilia gene therapies
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Go or no go? Novartis eyes a big new growth driver
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Bayer could become the latest casualty of Roche’s targeted pricing
Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.
Bluerock unlikely to smooth Bayer’s rocky road
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Upcoming events – catalysts approach for Catalyst and Oxurion
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Merck and the pitfalls of biopharma success
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.